- SPVN20 aims to restore visual acuity and aspects of color v…
Born from the Foundation Fighting Blindness, the RD (Retinal Degeneration) Fund was created to help accelerate life-changing outcomes for people with retinal degenerations through direct mission related investments in therapeutic companies. The mission of the Foundation Fighting Blindness is to rapidly drive the research that will lead to preventions, treatments and cures for retinal degenerative diseases – including retinitis pigmentosa, age-related macular degeneration, Usher syndrome and the entire spectrum of retinal degenerative diseases. Together, these blinding conditions affect more than 200 million people throughout the world.
IN THE NEWS
10/28/2025
SparingVision Doses First Patient with SPVN20 for Advanced Retiniti…
09/30/2025
Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase…
Pediatric participants demonstrated large gains in cone-medi…
09/23/2025
Atsena Therapeutics Announces Dosing Complete for Adults in Part B…
Pediatric dosing expected to begin in Q4 2025
Pivotal cohor…
09/12/2025
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial…
NPI-001 shows more than 50% reduction in photoreceptor loss …
07/23/2025
Opus Genetics and the Global RDH12 Alliance Partner to Advance RDH1…
- Collaboration aims to accelerate development of OPGx-RDH12,…
07/09/2025
Atsena Therapeutics Releases XLRS Community Statement
This morning, Atsena issued a press release to announce that…
06/23/2025
Opus Genetics Awarded Non-Dilutive Funding from the RD Fund to Supp…
RESEARCH TRIANGLE PARK, N.C., June 23, 2025 (GLOBE NEWSWIRE)…
06/09/2025
SparingVision appoints Dr. Kali Stasi as Chief Medical Officer
- Experienced global leader in ophthalmology and gene therapy…
04/08/2025
Opus Genetics Announces One-Month Clinical Data from Pediatric Pati…
First pediatric patient shows encouraging early safety profi…
04/02/2025
Atsena Therapeutics Announces Oversubscribed $150 Million Series C…
Financing led by new investor Bain Capital with participatio…
02/18/2025
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
First patient dosed in the pediatric cohort of the Phase 1/2…
02/18/2025
Perceive Pharma Attracts $15M Series A Financing to Advance Ophthal…
Funding to fuel company's progress in driving lead glaucoma …